Home › Funds › Casdin Capital › PRME
Casdin Capital position in PRME
PRIME MEDICINE INC · Health Care
Casdin Capital reported holding 3,167,175 shares of PRME (PRIME MEDICINE INC) in its Q3 2026 13F filing — a position valued at US$9.7M, representing 0.42% of its reported portfolio and ranking #33 among its reported holdings. Casdin Capital has disclosed PRME holdings in 16 of the last 16 reported quarters, going back to Q4 2022.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Casdin Capital's PRME position evolved
Casdin Capital first disclosed a stake in PRME in Q4 2022 at 734,350 shares (US$13.6M). The position peaked in Q3 2025 at 3,167,175 shares, worth US$17.5M. Across 16 filings, Casdin Capital increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 12 time(s). The most recent filing (Q3 2026) shows 3,167,175 shares valued at US$9.7M. Notable position changes include a 50% trim in Q2 2023 (shares fell 35% over the following quarter), a 327% increase in Q2 2025 (shares rose 124% over the following quarter), a 102% increase in Q3 2025 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2022 | 734.35K | $13.64M | New |
| Q1 2023 | 734.35K | $9.03M | Hold |
| Q2 2023 | 367.18K | $5.38M | Reduce |
| Q3 2023 | 367.18K | $3.50M | Hold |
| Q4 2023 | 367.18K | $3.25M | Hold |
| Q1 2024 | 367.18K | $2.57M | Hold |
| Q2 2024 | 367.18K | $1.89M | Hold |
| Q3 2024 | 367.18K | $1.42M | Hold |
| Q4 2024 | 367.18K | $1.07M | Hold |
| Q1 2025 | 367.18K | $730.68K | Hold |
| Q2 2025 | 1.57M | $3.87M | Add |
| Q3 2025 | 3.17M | $17.55M | Add |
| Q4 2025 | 3.17M | $10.99M | Hold |
| Q1 2026 | 3.17M | $11.02M | Hold |
| Q2 2026 | 3.17M | $11.69M | Hold |
| Q3 2026 | 3.17M | $9.68M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PRME and 13F data
PRME (PRIME MEDICINE INC) is a Health Care company. 33 other funds we track also report a position in PRME — the largest reported positions include ARCH Venture Management, LLC (US$56.5M), Alphabet Inc. (US$50.7M), Redmile Group, LLC (US$3.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PRME
- ARCH Venture Management, LLC 18.49M sh · $56.48M · Q3 2026
- Alphabet Inc. 16.56M sh · $50.68M · Q3 2026
- Redmile Group, LLC 1.15M sh · $3.50M · Q3 2026
- Alessandra Capital Management, LLC 800.77K sh · $2.45M · Q3 2026
More on Casdin Capital
FAQ
How long has Casdin Capital held PRME?
Casdin Capital has disclosed PRME holdings in 16 of the last 16 reported quarters, going back to Q4 2022.
What is Casdin Capital's current position in PRME?
As of Q3 2026, Casdin Capital holds 3.17M shares of PRME (PRIME MEDICINE INC), valued at $9.68M, representing 0.42% of its reported portfolio and ranking #33.
Has Casdin Capital been buying or selling PRME?
In the latest 13F filing (Q3 2026), Casdin Capital held unchanged its position in PRME. The position peaked in Q3 2025 at 3.17M shares.
Which other funds hold PRME?
Other major institutional holders of PRME include ARCH Venture Management, LLC, Alphabet Inc., Redmile Group, LLC, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.